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Objectives: R136K is a mutation of fibroblast growth factor-1 (FGF-1) in which arginine replaces lysine at the primary
thrombin cleavage site. This may be important in vivo in inducing endothelial cell (EC) migration and coverage of arterial
injury sites by allowing R136K to be used in a fibrin glue delivery system, without thrombin-induced degradation, in the
absence of heparin. The objectives of this study were to determine whether R136K, with and without heparin, can induce
migration of EC and smooth muscle cells (SMC) through fibrin glue, and to compare these results with those of wild-type
FGF-1; and to determine the resistance of R136K to thrombin-induced degradation versus FGF-1.
Methods: The dose-response migration through fibrin glue induced by wild-type FGF-1 and the R136K mutant in the
presence and absence of heparin was tested with EC and SMC. Migration was tested with 50, 100, and 200 ng/mL of
both FGF-1 and R136K, either with or without 5 U/mL of heparin. Migration of EC was also assessed after growth
inhibition with mitomycin C. A novel modified Boyden chamber-type migration assay using fibrin glue on the upper
surface of the chamber filter was used to test migration. The fluorescent marker calcein was used to identify those cells that
had migrated through the fibrin glue and were embedded in the filter. Molecular degradation by thrombin was assessed
with sodium dodecylsulfate polyacrylamide gel electrophoresis.
Results: For EC, R136K in the absence of heparin induced significantly more migration than did FGF-1 at 50 (P < .002),
100 (P < .0001), and 200 (P < .0001) ng/mL. In the presence of heparin, a chemotactic response of EC to cytokine was
seen at all doses, with no significant difference between FGF-1 and R136K. A dose-dependent difference was noted in this
group between the 100 and 200 ng/mL concentrations of cytokine (for FGF-1, P < .0001; for R136K, P < .0001). SMC
showed no difference in migration with FGF-1, R136K, or negative control at any dose in the presence or absence of
heparin. Gel electrophoresis demonstrated that R136K was more resistant to thrombin degradation than was FGF-1.
Conclusion: Site-directed mutagenesis of FGF-1 to R136K enables induction of heparin-independent migration of EC
through fibrin glue at an optimal concentration of 100 ng/mL. Neither FGF-1 nor R136K elicits SMC migration
through fibrin glue. The ability of R136K to induce EC migration through fibrin glue in the absence of heparin may prove
useful in vivo by inducing EC migration and coverage of arterial injury sites, thus potentially reducing thrombogenicity
and intimal hyperplasia. (J Vasc Surg 2003;37:1075-81.)
We have used fibrin glue for local delivery of bioactive
proteins in animal models of both vascular grafts and an-
gioplasty sites. In this test cytokines were mixed with fibrin-
ogen before adding thrombin, which cleaves fibrinogen to
fibrin. The glue is then directly placed at the site of desired
treatment, and cytokines are released as the fibrin glue is
degraded. Specifically, we have used this fibrin glue delivery
system to study the effects of fibroblast growth factor-1
(FGF-1) on recruitment of endothelial cells (EC) and on
intimal hyperplasia. In initial studies, FGF-1 plus heparin
delivered in fibrin glue enhanced endothelialization of ca-
nine aortoiliac and thoracoabdominal aortic expanded
polytetrafluoroethylene (ePTFE) grafts when compared
with fibrin glue alone or untreated grafts.1,2 However,
intimal thickness was increased at 20 weeks in grafts treated
with FGF-1.2
Encouraged by these results, we used site-directed mu-
tagenesis to create various FGF-1-based mutants. Site-
directed mutagenesis is an important technique that can
alter cytokine function and thereby elicit potentially bene-
ficial responses. The expectation is that with one or more of
these mutants FGF-1-induced endothelialization might be
maintained without stimulating intimal hyperplasia. Early
coverage of arterial injury sites and prosthetic vascular grafts
with a functioning endothelium may decrease thromboge-
nicity and intimal hyperplasia.3-6 This may in turn lead to
enhanced survival of bypass grafts.
R136K is a mutation of FGF-1 in which arginine re-
places lysine at the FGF-1 primary thrombin cleavage site.
In the absence of heparin, FGF-1 induces only mild prolif-
eration of SMC, whereas this proliferative effect is dramat-
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ically increased with addition of small amounts of heparin.
Heparin is required, however, when delivering wild-type
FGF-1 in fibrin glue, to protect it from thrombin-induced
cleavage. Because of its mutation at the primary thrombin
cleavage site, the R136K mutation may enable thrombin
resistance and heparin-independent activity on EC when
delivered in fibrin glue. Although most of our previous in
vitro studies focused on the mitogenic effects of FGF-1 and
its mutants, probably just as important is the ability of
FGF-1 mutants to induce EC migration through the fibrin
glue delivery vehicle and to the site of arterial injury or
endothelial denudation.
Toward this end, we developed a novel modified Boy-
den chamber to assess migration of EC and SMC through
fibrin glue. The objectives of this study were to determine
whether R136K, with and without heparin, can induce
migration of EC and SMC through fibrin glue and to
compare these results with those of wild-type FGF-1; and
to determine the resistance of R136K to thrombin-induced
degradation versus FGF-1.
MATERIALS AND METHODS
Materials
Chemicals and biologic agents. Chemicals and bio-
logic agents used included 0.05% trypsin/0.53 mmol/L
ethylenediamine tetraacetic acid (EDTA) and collagenase
from Gibco (Grand Island, NY); fibronectin, human
thrombin, human fibronogen, and FGF-1 from The Amer-
ican Red Cross (Rockville, Md); mitomycin C from Sigma
(St Louis, Mo); R136K mutant of FGF-1 from Clearant
(Rockville, Md); thiopental sodium from Abbott Labora-
tories (Morris Plains, NJ); bovine lung heparin from Phar-
macia & Upjohn (Kalamazoo, Mich); anti-von Willebrand
factor (vWF) antibody from Dako (Carpenteria, Calif);
anti--actin antibody from Sigma; and calcein AM from
Molecular Probes (Eugene, Ore).
Media. EC complete medium consisted of M199
(Gibco); 10% fetal bovine serum (FBS; Hyclone, Logan,
Utah); 100 U/mL of penicillin and 100 g/mL of strep-
tomycin (Gibco); FGF-1, 5 ng/mL; and heparin, 5 U/mL.
EC growth medium consisted of M199, 10% FBS, 100
U/mL of penicillin, and 100 g/mL of streptomycin.
EC quiescent medium consisted of Isocove modified
Dulbecco medium (Gibco); 2 nmol/L of L-glutamine
(Gibco); 5.5  105 mmol/L of 2-mercaptoethanol
(Gibco); 5% bovine serum albumin (Sigma); insulin-trans-
ferrin-selenium (insulin, 10 mg/mL; transferrin, 5.5 mg/
mL; selenium, 0.0067 mg/mL; Gibco); 100 U/mL of
penicillin; and 100 mg/mL of streptomycin.
SMC growth medium consisted of Dulbecco modified
Eagle medium (DMEM; Gibco), 10% FBS, 10 mmol/L of
L-nonessential amino acids (Gibco), 100 mmol/L of so-
dium pyruvate (Gibco), 50 g/mL of gentamicin (Gibco),
100 U/mL of penicillin, and 100 g/mL of streptomycin.
SMC quiescent medium consisted of DMEM:F12
(Gibco); insulin, 1 mol/L (Sigma); L-ascorbic acid, 0.2
mmol/L (Sigma); transferrin, 5 g/mL (Sigma); 100
U/mL of penicillin; and 100 g/mL of streptomycin.
Canine EC and SMC harvest
Animal care complied with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Re-
search Council, 1996) and the Principles of Laboratory
Animal Care (National Institutes of Health publ no. 85-23,
rev 1985).
Adult mongrel dogs were anesthetized with thiopental
sodium, intubation was carried out, and the lungs were
ventilated. Anesthesia was maintained with nitrous oxide
and halothane. Bilateral neck incisions were made. For EC,
bilateral external jugular veins were removed, inverted, and
processed according to our previously reported protocol.
In brief, the veins were sequentially placed in 0.05% tryp-
sin/EDTA 0.53 mmol/L and collagenase 100 U/mL at
37° C for 10 minutes each. After discarding the veins, the
trypsin and collagenase solutions were centrifuged, and the
pellets were resuspended in EC complete medium.
The EC were plated onto a fibronectin-coated T-25
culture flask (2.5 g/cm2) and incubated in a 37° C, 5%
CO2 chamber. Media were changed every 2 to 3 days, and
confluent cells were passaged with trypsin-EDTA. EC iden-
tity was confirmed with immunofluorescent dual staining
with vWF and -actin antibodies. Only EC exhibiting 95%
of positive vWF staining and 2% or less of -actin staining
were used for the assays. EC were used within passages 1 to
5.
SMC were obtained from canine carotid arteries with
our previously published explant technique. In brief, the
carotid arteries were opened longitudinally, and the intima
and adventitia were removed by scraping and dissecting
with a scalpel. The medial layer was minced and placed into
SMC growth media. Primary SMC migrating from the
explants were used in all experiments. SMC identity was
confirmed with immunoflourescent staining with -actin
antibodies, and only cultures exhibiting 95% or greater
positive staining were used in the proliferation assays.
Construction and purification of mutant FGF-1
The MORPH Site-Specific Plasmid DNA Mutagenesis
Kit (5 Prime–3 Prime, Boulder, Colo) was used to generate
the R136K mutant. The requirements for this system are
that double-stranded DNA is methylated and that there is
at least one Dpn I restriction site present. In brief, plasmid
DNA containing the FGF-1 gene was denatured and then
annealed in the presence of the phosphorylated mutagenic
primer CAAACGCGGTCCTAAAACTCACTATGGC-
CAG with T4 DNA polymerase and T4 DNA ligase. The
result is a double-stranded mutant plasmid containing the
original methylated template strand and a nonmethylated
replacement strand. At digestion with Dpn I, which will
digest only double-stranded methylated DNA, the mutant
plasmid DNA is left intact. DNA is transformed into Esch-
erichia coli mut S competent cells. The methylation-specific
repair system has been inactivated in E coli mut S; therefore
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it will not correct the nonmethylated mutant strand, and
that sequence will be propagated (approximately 50%).
R136K plasmid DNA was verified at automated DNA
sequencing. Further production and purification were per-
formed as described.7
Fibrin glue preparation
Fibrin glue was made by reconstituting lyophilized
human fibrinogen prepared from donor pooled plasma
with 1 Dulbecco phosphate-buffered saline solution
(PBS; Gibco), and polymerized with 1 Dulbeccos PBS
reconstituted lyophilized human thrombin, to make a final
concentration of 32 mg/mL and 0.32 U/mL, respectively.
For plates used to test the effect of cytokine plus heparin,
heparin was added so that the final concentration in the
fibrin glue was 5 U/mL.
EC and SMC migration assay
Fibrin glue was prepared as described, and 20 mL was
placed on the upper filter surface of Costar transwell poly-
styrene plates (8.0 mm pore size in polycarbonate mem-
brane; Corning Inc, Corning, NY). After allowing the
fibrin glue to polymerize for 8 minutes, 600 mL of growth
medium was added to the lower chamber. Confluent cells
were then trypsinized and seeded on top of the fibrin glue at
80,000 cells/well in 100 mL of medium. After 24 hours
the medium in the lower chamber was changed to quies-
cent medium: control wells contained quiescent medium
only; test wells contained quiescent medium plus cytokine
in concentrations of 50, 100, and 200 ng/mL, with or
without heparin at 5 U/mL. After 48 hours of migration,
the medium in the upper and lower chambers was gently
suctioned off and the fibrin glue, along with the nonmigra-
tory cells, was scraped from the filter with a cotton-tipped
applicator. The filters were washed twice with 1 PBS.
Then 2 mmol/L of Calcein AM (600 mL) (Molecular
Probes, Eugene, Ore) was added to the lower chamber for
30 minutes at 37° C and allowed to metabolize to its
fluorescent counterpart, calcein. Fluorescence was quanti-
tated with a fluorescence plate reader (excitation 480 nm,
emission 530 nm; Cytofluor; PerSeptive Biosystems, Fra-
mingham, Mass). Each concentration was tested in repli-
cates of four, and each experiment was repeated in tripli-
cate, with similar results. Results were normalized to
negative control and were expressed as percentage of neg-
ative control after subtracting out the background fluores-
cence.
EC migration assay with growth inhibitor
EC were exposed to mitomycin C at 10 mg/mL for 1
hour to inhibit growth. To document growth inhibition,
10,000 cells/well were seeded to 96-well polystyrene plates
in EC growth medium. Test wells were treated with myto-
mycin C; control wells were not. After 3 days the cell
number in each well was quantitated by washing with PBS,
followed by adding 2 mmol/L of Calcein AM (100 mL) to
each well. Calcein AM was allowed to metabolize to its
fluorescent counterpart, calcein, and results were deter-
mined with a fluorescence plate reader as described above.
Results are expressed as percentage of fluorescence of my-
tomycin C-treated cells versus nontreated cells.
The migration assay was performed with the above
described technique, with the exception that only EC were
tested, and they were treated with mytomycin C for 1 hour
at 10 mg/mL before seeding.
Molecular degradation with thrombin
Purified recombinant FGF-1 and R136K (20 mg) were
resuspended in 0.05 mol/L of HEPES (N-2-hydroxyeth-
ylpiperazine-N-2-ethanesulfonic acid) buffer, 0.25 mol/L
of sodium chloride, and 5 mmol/L of calcium chloride (pH
7.5; 600 mL) in the presence of 6 U of thrombin. The
samples were incubated at 37° C for 4, 8, 16, and 24 hours.
Aliquots (100 mL) were mixed with 20 mL of 6 Lae-
mmlis sample buffer. The samples were subjected to so-
dium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) with 15% polyacrylamide gels, under reduc-
ing conditions. The gels were stained with Coomassie
brilliant blue to visualize intact cytokine and dissolved
fragments.
Statistical analysis
Statistical analysis was performed with the Student t test
and one-way analysis of variance, as appropriate.
RESULTS
EC migration assay. When comparing R136K with
FGF-1 without heparin, R136K induced significantly more
migration at all concentrations (at 50 ng/mL, P .002; at
100 and 200 ng/mL, P .0001). Both R136K and FGF-1
induced significantly less migration without heparin than
with heparin (FGF-1, P  .0001 at all doses. R136K at 50
ng/mL, P .001; at 100 ng/mL, P .03; at 200 ng/mL,
P  .0001) (Fig 1, A).
In the presence of heparin, a chemotactic response of
EC through fibrin glue was seen with all tested concentra-
tions of R136K and FGF-1 (Fig 1, B). A dose-dependent
difference was noted in this group between the 100 ng/mL
and 200 ng/mL doses (for FGF-1, P .0001; for R136K,
P  .0001). No significant difference in migration was
induced between FGF-1 and R136K in the presence of
heparin.
SMC migration assay. Neither cytokine induced any
detectable migration through fibrin glue over negative
control at any concentration tested. The presence or ab-
sence of heparin had no effect on this result (Fig 2).
EC migration assay with growth inhibitor. Treat-
ing EC with mytomycin C for 1 hour at 10 mg/mL
resulted in inhibition of EC proliferation, with treated cell
fluorescence only 41.7% 12.2% compared with untreated
cells after 3 days of growth. When comparing R136K with
FGF-1 without heparin, R136K induced significantly more
migration at all concentrations (P  .001) (Fig 3, A).
In the presence of heparin, a chemotactic response of
EC through fibrin glue was seen with all tested concentra-
tions of R136K and FGF-1 (FGF-1 at 50 ng/mL, 157.8%
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 35.2%; at 100 ng/mL, 188.5% 58.0%; at 200 ng/mL,
207.5%  64.5%. R136K at 50 ng/mL, 174.4%  22.6%;
at 100 ng/mL, 198.9% 26.6%; at 200 ng/mL, 246.5%
43.2%). There was no significant difference in migration
induced between FGF-1 and R136K in the presence of
heparin (Fig 3, B).
Molecular degradation with thrombin. Results of
SDS-PAGE analysis of both R136K and FGF-1 after
thrombin digestion are shown in Fig 4. Both cytokines
were incubated with thrombin for 4, 8, 16, and 24 hours at
37° C. At 4 hours there was a band at 17 kDa that
corresponded to R136K and FGF-1. Both cytokines
showed thrombin degradation over time; however, the
R136K mutant was relatively more thrombin resistant,
especially at 16 and 24 hours, as demonstrated by increased
density of fragments with R136K versus FGF-1.
DISCUSSION
Vascular interventions have attained a high degree of
technical sophistication, and nearly every vascular bed is
amenable to invasive therapy. Nevertheless, little progress
has been made in reducing or preventing intimal hyperpla-
sia, which remains the primary cause of failure of implanted
vascular grafts and stents. In addition, no reliable and
practical method exists to induce coverage of prosthetic
grafts with functioning endothelium. Such coverage might
result in decreased thrombogenicity and thereby increased
patency of grafts.
One possible approach to reducing intimal hyperplasia
or inducing endothelial coverage involves local application
of cytokines to modulate events at the site of arterial injury.
To deliver these cytokines locally, we developed a fibrin
glue delivery system. In this fibrin glue, cytokines are mixed
with fibrinogen before adding thrombin, which cleaves the
fibrinogen to fibrin. The glue is then placed at the treat-
ment site, and the cytokines are released as the fibrin glue is
degraded. We have performed in vivo experiments to quan-
titate the release kinetics of iodine 125-FGF-1 from fibrin
glue impregnated in ePTFE grafts. During the first hour
the rate of loss of 125I-FGF-1 averaged 24.1% per minute,
and the rate of loss from 60 minutes to 30 days averaged
.03% per minute. When delivered along with 33 U/mL of
heparin, at 7 days of circulation 13.4%  6.9% of the
cytokine remained on the prosthesis, and at 30 days 4%
remained.8
Subsequently we used this fibrin glue delivery system to
study the effects of FGF-1 on intimal hyperplasia. Initial
studies showed that FGF-1 plus heparin delivered in fibrin
glue enhances endothelialization of canine aortoiliac and
thoracoabdominal aortic ePTFE grafts, compared with fi-
brin glue alone or untreated grafts.1,2 However, intimal
thickness was increased at 20 weeks in FGF-1-treated
grafts.2
Because vascular endothelial growth factor (VEGF) is
EC-specific, it has been the focus of much effort to use
locally delivered cytokines to modulate intimal hyperplasia.
Fig 1. A, Migration of EC through fibrin glue in response to FGF-1 versus R136K in absence of heparin. R136K
induced more migration than FGF-1 did at all concentrations in absence of heparin. *P  .002; **P  .0001. B,
Migration of EC through fibrin glue in response to FGF-1 versus R136K in presence of 5 U/mL of heparin.
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Topical application of VEGF attenuates intimal hyperplasia
in both rat and rabbit models.9-11 In a canine balloon injury
model, we demonstrated increased EC coverage at 10 and
30 days with VEGF delivered in fibrin glue. In this study,
however, we found increased intima/media thickness ratios
in VEGF-treated arteries at 30 and 90 days.12 This was
believed to be a result of VEGF-induced alteration in EC
phenotype and secondary promotion by EC of intimal
hyperplasia. Despite its specificity, VEGF is a relatively
weak EC mitogen; thus we focused our efforts on studying
FGF-1. FGF-1 is a more potent EC mitogen than VEGF,
yet it lacks cell specificity. In the absence of heparin, FGF-1
induces only mild SMC proliferation, but with the addition
of small amounts of heparin this effect increases dramati-
cally. Heparin is required for our fibrin glue delivery system
to prevent thrombin degradation of FGF-1. Site-directed
mutagenesis might obviate this need for heparin and
thereby generate FGF-1 mutants capable of inducing en-
dothelialization without inducing SMC proliferation.
The first FGF-1 mutant we generated and tested was
cysteine-free FGF-1.13 In the cysteine-free mutant, all
three cysteine residues of FGF-1 (positions 30, 97, 131) are
converted to serine residues. This new cysteine-free FGF-1
mutant showed increased susceptibility to thrombin diges-
tion, yet induced heparin-independent proliferation of
both EC and SMC in a dose-dependent manner. At 100
ng/mL the cysteine-free mutant induced 4-fold prolifera-
tion on EC and 12-fold proliferation on SMC than did
wild-type FGF-1. Another FGF-1 mutant tested was
S130K.14 S130K has a serine to lysine residue change at
position 130 (residues 122-137 are a major heparin-bind-
ing domain of FGF-1). S130K exhibited some increased
resistance to thrombin degradation at SDS-PAGE. It also
elicited heparin-independent proliferation of EC and SMC,
and was more potent than FGF-1 in the presence of heparin
at lower concentrations. Both of these FGF-1 mutants
demonstrate that site-directed mutagenesis can produce
important alterations in cytokine functions.
We have developed an FGF-1 mutant with an arginine
to lysine change at the primary thrombin cleavage site of
FGF-1 (residue 136). We hypothesized that this R136K
mutant would have increased resistance to thrombin deg-
radation, which would enable it to elicit responses in the
presence of thrombin, ie, in fibrin glue, without heparin.
When SDS-PAGE was performed on R136K it did
indeed show increased resistance to thrombin degradation,
as evidenced by increased density of fragments with R136K
versus FGF-1 over time. This was especially evident at later
time points.
Although to date most of our in vitro studies have
focused on the proliferative effects of FGF-1 and its mu-
tants, probably just as important is the ability of these
Fig 2. A, Migration of SMC through fibrin glue in absence of heparin. No difference between concentrations or when
compared with negative control was noted. B, Migration of SMC through fibrin glue in presence of 5 U/mL of
heparin. No difference between concentrations or when compared with negative control was noted.
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cytokines to induce EC migration through or under the
fibrin glue delivery system. This is important if the cyto-
kines are to elicit endothelialization after endothelial de-
nuding injuries such as angioplasty and endarterectomy.
Early coverage of arterial injury sites and vascular prostheses
with a functioning endothelium may decrease intimal hy-
perplasia.3-6
To test ability of R136K to induce EC migration
through fibrin glue, we developed a novel modified Boyden
chamber, which uses 20 mL of fibrin glue on the upper
surface of the chamber filter. After 48 hours of migration
the fibrin glue and nonmigratory cells are removed, and
migratory cells embedded in the filter are quantitated with
the fluorescent marker calcein.
When testing R136K versus FGF-1 on EC in the
presence of heparin, dose-dependent migration of EC
through the fibrin glue was observed. No difference was
noted between FGF-1 and R136K in the presence of hep-
arin. It is possible that some of the observed migration in
this group was induced by the heparin itself, in addition to
a synergistic effect of cytokine and heparin. In the absence
of heparin, both cytokines induced significantly less migra-
tion than with heparin. Nevertheless, R136K elicited more
migration than FGF-1 did at all tested doses in the absence
of heparin. A maximal response for R136K was observed at
100 ng/mL in the absence of heparin. In addition, R136K
maintained this heparin-independent activity even after
inhibition of EC growth with mytomycin C. In contrast to
EC, neither FGF-1 nor R136K induced migration of SMC
through fibrin glue, compared with negative controls. The
presence or absence of heparin had no effect on this result.
This is similar to findings in our earlier study that tested EC
and SMC migration through fibrin glue in response to
FGF-1 and heparin.15 This study used an under fibrin glue
migration assay, with direct assessment of distance and area
of cell migration. In this study, SMC were relatively unable
to penetrate under the fibrin glue and instead tended to
climb up and over the glue. As opposed to SMC, EC were
able to penetrate under the fibrin glue even at the lower
cytokine doses. This may be related to production of tissue
plasminogen activator (t-PA) by EC.16 This t-PA produc-
tion may enable EC to digest and traverse the fibrin glue to
a greater extent than the SMC can. Lack of SMC migration
through fibrin glue does not eliminate the possibility of
proliferation of SMC in response to R136K directly at the
site of arterial injury. Nevertheless, development of an
FGF-1 mutant that induces heparin-independent migra-
tion of EC through fibrin glue is an important first step,
given the known reduced mitogenic effects of FGF-1 on
SMC in the absence of heparin. On the basis of positive
results of these experiments, in vivo experiments will be
planned to determine whether these in vitro observations
Fig 3. A, Migration of EC through fibrin glue in response to FGF-1 versus R136K in absence of heparin after growth
inhibition with mytomycin C. R136K induced more migration than FGF-1 did at all concentrations in absence of
heparin (P  .0001). B, Migration of EC through fibrin glue in response to FGF-1 versus R136K in presence of 5
U/mL of heparin after growth inhibition with mytomycin C.
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will result in a significant difference in endothelial coverage
of prosthetic grafts or intimal thickening.
We conclude that the R136K mutant of FGF-1 enables
heparin-independent migration of EC through fibrin glue
at an optimal concentration of 100 ng/mL. In the presence
of heparin, both R136K and wild-type FGF-1 elicit EC
migration through fibrin glue in a dose-dependent manner.
Heparin-independent activity and thrombin resistance of
the R136K mutant suggests potential clinical efficacy if
delivered to the site of vascular intervention.
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Fig 4. Molecular degradation of FGF-1 (A) and R136K (B) by thrombin. FGF-1 and R136K were incubated with
thrombin for 4, 8, 16, and 24 hours and analyzed with SDS-PAGE. At 4 hours a band is seen at 17 kDa,
corresponding to undigested R136K and FGF-1 (arrow). Both cytokines showed thrombin degradation over time;
however, the R136K mutant was relatively more thrombin resistant, especially at 16 and 24 hours, as demonstrated by
increased density of the band at 17 kDa with R136K versus FGF-1 at later time points.
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